FDA Approves AbbVie's Tavapadon as First Selective D1/D5 Agonist for Parkinson's Disease
Juvmo (tavapadon) wins FDA approval for Parkinson's, offering once-daily dosing alone or with levodopa and meaningful gains in daily 'on' time.
Summary
The FDA has approved AbbVie's Juvmo (tavapadon) for adults with Parkinson's disease, making it the first selective D1/D5 dopamine receptor agonist cleared for this condition. It can be taken once daily with or without levodopa. Phase 3 TEMPO trial data showed adults in early Parkinson's experienced improvements in daily living activities, while those using it alongside levodopa gained roughly 1.7 extra hours of 'on' time without troublesome involuntary movements compared to 0.6 hours on placebo. Off time also fell by 1.9 versus 0.9 hours. Efficacy held through 85 weeks of follow-up. Side effects were mostly mild to moderate, including nausea, dizziness, and headache. The drug is expected to reach U.S. patients in October 2026.
Detailed Summary
Parkinson's disease affects more than 11 million people worldwide and is among the most common neurodegenerative conditions associated with aging. Effective symptom management is central to preserving quality of life and functional independence for those living with the disease, making new therapeutic options an important advance in the longevity and healthspan space.
The FDA has approved Juvmo (tavapadon) tablets from AbbVie to treat adults with Parkinson's disease. Juvmo is notable as the first and only selective D1/D5 dopamine receptor agonist to receive approval for this indication. Its selective mechanism differentiates it from existing dopamine agonists, which typically target D2/D3 receptors and carry significant risks of side effects such as impulse-control disorders and excessive sedation.
Approval was based on Phase 3 TEMPO program data. In early Parkinson's, tavapadon improved activities of daily living compared to placebo. When used as an adjunct to levodopa — the cornerstone of Parkinson's therapy — patients gained an average of 1.7 additional hours of 'on' time without troublesome dyskinesia versus 0.6 hours for placebo at 26 weeks, and reduced 'off' time by 1.9 hours compared to 0.9 hours for placebo. Sustained efficacy was observed through 85 weeks of treatment.
The safety profile appeared manageable. Most treatment-emergent adverse events were non-serious and mild to moderate in severity. Common events included nausea, headache, dizziness, fatigue, altered taste, vomiting, dry mouth, anxiety, dyskinesia, and hallucinations — consistent with the dopaminergic drug class.
Juvmo will be available in 5 mg, 10 mg, and 15 mg tablets plus titration packs, with U.S. availability expected in October 2026. For aging adults and clinicians managing Parkinson's, a once-daily selective D1/D5 agonist that can complement levodopa without dramatically increasing dyskinesia risk represents a meaningful addition to the therapeutic toolkit.
Key Findings
- Tavapadon is the first FDA-approved selective D1/D5 dopamine receptor agonist for Parkinson's disease.
- Adjunct use with levodopa added 1.7 hours of daily 'on' time without troublesome dyskinesia vs. 0.6 hours for placebo.
- Total daily 'off' time was reduced by 1.9 hours with tavapadon versus 0.9 hours for placebo at week 26.
- Efficacy was sustained through 85 weeks; most adverse events were mild to moderate.
- Once-daily dosing with or without levodopa may simplify treatment regimens for patients.
Methodology
This is a news report summarizing an FDA approval announcement from AbbVie. Evidence is drawn from the Phase 3 TEMPO clinical trial program; specific trial publications or full data packages should be consulted for detailed methodology and statistical outcomes.
Study Limitations
The article is a company-issued news summary without full statistical detail or peer-reviewed publication citation. Long-term comparative data against existing dopamine agonists is not presented, and real-world effectiveness and safety may differ from controlled trial conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: